Transarterial catheter double-targeted drug delivery monitoring and controlling system based on video supervision

Abstract

The invention relates to a transarterial catheter double-targeted drug delivery monitoring and controlling system based on video supervision. The system comprises a living body information collectingmodule, a drug delivery instruction module, a via-tumor feeding artery drug delivery module and a living body evaluation module. The living body information collecting module is used for collecting living body state information. The drug delivery instruction module is used for generating a drug delivery instruction based on the living body state information. The via-tumor feeding artery drug delivery module executes the drug delivery instruction and is used for carrying out echeloning drug delivery of tumor vessel disrupters and radiolabeled necrosis affinity agents on a living body through alocal tumor feeding artery. The living body evaluation module is used for comprehensively evaluating the living body according to the state information of the living body after drug delivery is carried out, and an instruction for determining whether a drug is repeatedly delivered is generated and sent to the drug delivery instruction module. Compared with the prior art, the system has the advantages of being convenient to use, safe, reliable and the like, under the safe dose of systemic drug delivery, the local drug concentration on a focus is greatly increased, and therefore the treatment effect is greatly improved, and the toxic and side effects of other visceral organs are reduced.

Description

technical field [0001] The invention relates to the field of medical detection systems, in particular to an image-guided dual-target drug delivery monitoring and control system through an arterial catheter. Background technique [0002] In the field of tumor treatment, after traditional intravenous administration, the route and sequence of anticancer drug distribution in the body is "peripheral vein → vena cava → right atrium → right ventricle → pulmonary circulation → left atrium → left ventricle → systemic circulation → tumor focus" Therefore, the local concentration of the drug at the end of the cancer focus is far lower than the blood concentration at the time of injection. While the efficacy of the drug treatment gradually decreases, the initial blood flow through the heart, lungs and other normal organs suffers from considerable drug toxicity. . Take the tumor vascular disrupting agent (VDA) Compretastatin A4 phosphate (CA4P) as an example, this type of drug can quick...

AI Technical Summary

Problems solved by technology

[0005] However, how to further break through the above-mentioned limitations in the treatment of different types of solid tumors and efficacy monitoring, and how to obtain a more optimized therapeutic effect is still worthy of in-depth research in this field

Images